Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AQST vs NUVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AQST Captures Overall Composite Edge (62.9 BUY vs 61.0 BUY), While NUVB Leads 3–2 on Growth & Valuation Pillars

AQST Overall Winner 6-Pillar Tally: AQST 2 – 3 NUVB (1 Tie) Matrix Metrics: AQST 3 – 5 NUVB

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (62.9/100 BUY vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus NUVB at $3.80 (N/M Forward P/E, -61.2% operating margin).

  • Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. NUVB 61.0/100 BUY) and 0.89β · 56% Vol risk profile, whereas NUVB leads top-line expansion (+242.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AQST vs NUVB
AQST NASDAQ Head-to-Head Winner
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
TTM Revenue $49M
Forward P/E N/M
Beta / 30D Vol 0.89β · 56% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 36
RSI-14: 36.5 · SMA20: $3.77 · SMA50: $4.23
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
TTM Revenue $202M
Forward P/E N/M
Beta / 30D Vol 1.52β · 55% Vol
Unified Composite Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $4.28 · SMA50: $4.87

6-Pillar Scorecard Institutional Category Breakdown (AQST 2 – 3 NUVB)

Columns: Metric · AQST · NUVB
1. Valuation Multiples NUVB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 8.9x 7.4x
2. Growth & Scale NUVB
Revenue Growth (YoY) -41.0% +242.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $49M $202M
Market Cap $465.7M $1.3B
3. Profitability & Quality NUVB
Gross Margin 65.3% 85.8%
Operating Margin -114.1% -61.2%
Net Profit Margin -162.3% -67.4%
Return on Equity (ROE) 0.0% -49.1%
4. Balance Sheet & Cash Flow AQST
Cash Generation (TTM) -$41M -$108M
Cash Flow Margin -83.3% -53.6%
Net Cash / Leverage $32M Net Cash $146M Net Debt (1.32x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AQST
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 87.9% (64th %ile) 65.2% (26th %ile)
Put/Call OI Skew 0.98x (Balanced) 0.24x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AQST (3) vs NUVB (5)
Institutional Metric AQST NUVB Criterion Row Edge
Market Capitalization
Scale
$465.7M $1.3B Larger Scale NUVB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-41.0% +242.6% Higher Growth NUVB
Operating Margin (TTM)
Profitability
-114.1% -61.2% Higher Margin NUVB
Net Profit Margin
Profitability
-162.3% -67.4% Higher Margin NUVB
Return on Equity (ROE)
Capital Efficiency
0.0% -49.1% Higher ROE AQST
52-Week Range Position
Momentum
14% ($3–$7) 2% ($4–$10) Stronger Trend AQST
Beta / 30D Volatility
Risk Regime
0.89β · 56% Vol 1.52β · 55% Vol Lower Realized Risk NUVB
Unified Institutional Score
Composite Signal
62.9 / 100 (BUY) 61.0 / 100 (BUY) Higher Composite AQST
Trailing 12M Revenue (USD)
Operating Scale
$49M $202M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
65.3% 85.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.9x EV/Rev N/M PEG · 7.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$41M ($32M Net Cash) -$108M ($146M Net Debt (1.32x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AQST +2.93 pp
AQST: -16.22% · NUVB: -19.15%
3M Horizon AQST +15.87 pp
AQST: -27.92% · NUVB: -43.79%
6M Horizon AQST +3.47 pp
AQST: -16.02% · NUVB: -19.49%
1Y Horizon AQST +6.2 pp
AQST: -40.65% · NUVB: -46.85%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AQST Revenue NUVB Revenue AQST Op. Margin NUVB Op. Margin Margin Leader
FY2018 $70M N/A -72.6% N/A AQST
FY2019 $50M N/A -100.1% N/A AQST
FY2020 $50M N/A -93.6% N/A AQST
FY2021 $50M N/A -68.2% N/A AQST
FY2022 $50M N/A -88.2% N/A AQST
FY2023 $50M N/A -29.9% N/A AQST
FY2024 $60M $10M -53.5% -7527.3% AQST
FY2025 $40M $60M -159.5% -338.7% AQST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AQST BREAKDOWN
61d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 64th %ile
Put/Call OI Skew 0.98x (Balanced)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AQST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUVB BREAKDOWN
105d in phase · OBV DISTRIBUTION
Current IV 65.2%
IV Percentile 26th %ile
Put/Call OI Skew 0.24x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NUVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AQST Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $465.7M market capitalization and -114.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NUVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -61.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AQST vs NUVB Key Questions & Quantitative Answers

As of Nov 20, 2026, Aquestive Therapeutics, Inc. (AQST) captures the overall head-to-head institutional edge over Nuvation Bio Inc. (NUVB) on higher Unified Composite conviction (62.9/100 BUY vs. 61.0/100 BUY) after splitting the core matrix 3–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NUVB wins 3–2 across the 6-pillar growth and valuation breakdown. AQST trades at $3.46 (N/M Forward P/E, -114.1% operating margin) versus NUVB at $3.80 (N/M Forward P/E, -61.2% operating margin). Growth vs. Quality Trade-Off: AQST earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. NUVB 61.0/100 BUY) and 0.89β · 56% Vol risk profile, whereas NUVB leads top-line expansion (+242.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: AQST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 36.5); meanwhile NUVB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NUVB leads the Growth & Scale pillar: AQST posts -41.0% YoY revenue growth and +0.0% YoY earnings growth on $49M TTM revenue (65.3% gross margin, -114.1% operating margin), compared with NUVB at +242.6% YoY revenue growth and +0.0% YoY earnings growth on $202M TTM revenue (85.8% gross margin, -61.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AQST cumulative revenue shifted -42.9% while NUVB shifted +500.0%. In operating R&D and SG&A reinvestment, AQST deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUVB.

NUVB screens cheaper on headline valuation multiples. AQST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.9x EV/Revenue (-83.3% FCF margin), whereas NUVB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.4x EV/Revenue (-53.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AQST (0.0% ROE) versus NUVB (-49.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AQST carries 87.9% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 0.98x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 56% Vol realized risk). By comparison, NUVB carries 65.2% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.52β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.